Clinical trials: Neoadjuvant Therapy in Rectal Cancer
Rectal Tumors, Rectal Cancer
Organ-sparing With TraceIT® for Rectal Cancer Radiotherapy
For advanced rectal tumors, the standard of care is neoadjuvant radiotherapy (RT) +/- chemotherapy followed by surgery 8-10 weeks later.
- Conditions
- Rectal Tumors, Rectal Cancer, Advanced Cancer
- Trial name
- NCT03258541
- Testing
- TraceIT®, Volumetric Arc Therapy (VMAT), Surgery
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- Thomas Zilli
Rectal Cancer
Targeted Optical Biopsy for Local Rectal Scars in Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy
Currently, low concordance (36%) is found between clinical complete response and pathologic complete response in patients with rectal cancer after neoadjuvant chemoradiotherapy.
- Trial name
- NCT05316103
- Testing
- Probe-based confocal laser endomicroscopy targeted optical biopsy
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Nanfang Hospital, Southern Medical University
To Observe Whether the Fucoidan Can Improve the Quality of Life of the Such Patients Receiving the Neoadjuvant CCRT
The Auxiliary Effects of Fucoidan for Locally Advanced Rectal Cancer Patients
This is a double-blind, randomized, placebo-controlled, parallel study. The main goal is to investigate the auxiliary effects of Fucoidan for the patients with locally advanced rectal cancer who receive neoadjuvant CCRT before…
- Trial name
- NCT04342949
- Testing
- quality of life
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Colorectal Cancer
Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC
This study determine the maximal tolerate dose
- Trial name
- NIPOX (NCT03253133)
- Testing
- Oxaliplatin, LV5FU or Folfiri, Oxycodone
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Rectal Cancer
Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial
Currently the 3-year disease free survival of patients with locally advanced rectal cancer is about 50%. Current standard treatment for patients at high risk of failing locally and/or systemically includes pre-operative long…
- Trial name
- RAPIDO (NCT01558921)
- Testing
- M1 scheme, standard long course chemoradiotherapy
- Where
- 56 sites in United States, Denmark and 5 more
- Volunteers
- 920 people
- Sponsor
- University Medical Center Groningen
Rectal Cancer, Total Neoadjuvant Treatment
Short-course Radiotherapy With Induction and Consolidation Chemotherapy in Patients With Locally Advanced Rectal Cancer
Short-course radiotherapy followed by consolidation chemotherapy has shown a better response rate when compared to chemoradiotherapy treatment.
- Trial name
- SHORT-ICAR (NCT04674696)
- Testing
- Approach
- Where
- Brazil
- Volunteers
- 54 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
MSS-type Low Rectal Cancer，Neoadjuvant Chemoradiotherapy, QL1706
Neoadjuvant Chemoradiotherapy Combined With QL1706 for MSS-Type Low-Rectal Cancer
he goal of this prospective, exploratory clinical trial is to learn if neoadjuvant chemoradiotherapy combined with QL1706 (a dual PD-1/CTLA-4 antibody) can effectively treat in patients with MSS-type low rectal cancer (tumor…
- Trial name
- NCT07866313
- Testing
- Neoadjuvant short-term radiotherapy and chemotherapy + iparomlimab and tuvonralimab, Neoadjuvant long-term radiotherapy and chemotherapy + iparomlimab and tuvonralimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changhai Hospital
Colorectal Cancer
Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00081289
- Testing
- Radiation Therapy, Capecitabine 1650 mg/m^2/day, Capecitabine 1200 mg/m^2/day
- Where
- 5 sites in United States
- Volunteers
- 146 people
- Sponsor
- Radiation Therapy Oncology Group
Locally Advanced Rectal Cancer
Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer
The study evaluates the addition of Amifostine to capecitabine and irinotecan in neoadjuvant chemoradiation(CRT) in locally advanced rectal cancer.
- Trial name
- NCT03702985
- Testing
- Radiation, Capecitabine, Irinotecan
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University
Rectal Cancer Stage II, Rectal Cancer Stage III
Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer
This is a multicenter, single-arm, phase II study of nivolumab in combination with regorafenib in subjects with locally-advanced rectal cancer who are eligible for a curative treatment including pre-operative SCRT and TME(or…
- Trial name
- REGINA (NCT04503694)
- Testing
- Nivolumab 10 MG/ML Intravenous Solution, Regorafenib 30 MG Oral Tablet, Radiotherapy
- Where
- 9 sites in Belgium
- Volunteers
- 72 people
- Sponsor
- Jules Bordet Institute
Rectal Neoplasms
Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
This study aims to evaluate the efficacy and safety of tislelizumab combined with simultaneous integrated boost intensity-modulated radiotherapy in treating locally advanced rectal cancer.
- Trial name
- NCT06017583
- Testing
- Tislelizumab, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Yong Zhang,MD
Rectal Neoplasm
Radiotherapy & Total Neoadjuvant Therapy for Recurrent Rectal Cancer in Previously Irradiated Patients, an Italian Association for Radiotherapy and Clinical Oncology (AIRO)-GI Platform: a Multi-centre Prospective Observational Study
The introduction of neoadjuvant chemoradiation therapy (CRT) and the use of advanced surgical techniques have led to a reduction in mortality and recurrence rates for rectal cancer, the rate of which currently stands at 4-8%.
- Trial name
- RETRY (NCT05984576)
- Testing
- Reirradiation
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rectal Cancer Stage, Oesophageal Cancer
PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer
The overall aim of this pilot study is to prospectively monitor programmed death-ligand 1 (PD-L1) expression dynamics in vivo, during neoadjuvant chemoradiotherapy (CRT) or short-course preoperative radiotherapy (SCPRT) in rectal…
- Trial name
- PETNEC (NCT04564482)
- Testing
- CRT, SCPRT, CROSS Protocol
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Johannes Laengle, MD, PhD
Rectal Cancer
Total Neoadjuvant Therapy in Rectal Cancer
In this phase 2 study, the efficacy of total neoadjuvant therapy in Taiwanese patients with rectal cancer will be investigated. Patients with stage II or III middle/low rectal cancer will be prospective enrolled.
- Trial name
- NCT06162650
- Testing
- Short-course radiotherapy, mFOLFOX6
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- National Cheng-Kung University Hospital
RECTAL NEOPLASMS, Rectal Cancer
Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study
This is an open-label, multi-center, single-arm clinical study. All patients received concurrent chemoradiation therapy (CRT) followed by 4 cycles of tislelizumab combined with CAPOX, then underwent clinical response assessment.
- Trial name
- NCT06390982
- Testing
- Radiotherapy, Tislelizumab, Capecitabine
- Volunteers
- 46 people
- Sponsor
- Fudan University
Neoadjuvant Chemoradiotherapy, Rectal Tumor
Outcomes of Resection at Different Times Between the End of Neoadjuvant Treatment and Surgery
Neoadjuvant radio-chemotherapy (NRCT) represents a milestone in the treatment of selected rectal tumours. Ideal time interval between the end of NRCT and surgery is still debated; a 6-8 weeks time interval is considered optimal…
- Conditions
- Neoadjuvant Chemoradiotherapy, Rectal Tumor, Surgery, Surgery--Complications
- Trial name
- NCT04013347
- Testing
- Rectal Resection
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- Campus Bio-Medico University
Rectal Cancer
Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)
This multicenter, randomized controlled clinical trial (FIRM02 Study) aims to evaluate the effectiveness and safety of neoadjuvant mFOLFOX6 chemotherapy combined with PD-1 inhibitor (Serplulimab) in patients with MSS/pMMR locally…
- Trial name
- NCT07381400
- Testing
- mFOLFOX6, Serplulimab
- Volunteers
- 128 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
This phase I trial studies the best dose and side effects of talimogene laherparepvec in combination with 5-fluorouracil, leucovorin, oxaliplatin, capecitabine, and chemoradiation before surgery in treating patients with rectal…
- Conditions
- Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Rectal Adenocarcinoma, Stage III Rectal Cancer AJCC v7
- Trial name
- NCT03300544
- Testing
- Capecitabine, Fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer, Lymph Node Metastasis
Clinical Relevance of Pathologic Regression IN Lymph Node for Locally Advanced Rectal Cancer
We evaluated all related clinical and pathologic data of patients with Locally Advanced Rectal Cancer following Neoadjuvant Chemoradiotherapy, including the pathologic regression grading in the primary tumor site and lymph node…
- Trial name
- NCT06883084
- Volunteers
- 1,080 people
- Sponsor
- Yanhong Deng
Colorectal Cancer
Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00086931
- Testing
- capecitabine, oxaliplatin, conventional surgery
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Roswell Park Cancer Institute